Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| First of all, we don't necessarily guide quarter-to-quarter, but I assume you're very pleased with our full year guide |
| And we're seeing a really positive response and positive process |
| And with that, we'll -- with really big technology like that, we'll gain price, we'll gain market share, and there'll be really good momentum |
| We feel good about that |
| And so I think that -- and competitively, we're in a good position for LIFEPAK, just given where some of our competitors are in the market right now, too |
| And so we'll start to see really good payback and performance and ability to leverage those things as we move forward to |
| And frankly, if you think about these products, the more market adoption we see and the more they get out in the market, then we get a little bit of a halo and a buzz because docs talk, nurses talk, clinicians talk and it just drives really good momentum for those products |
| They should be very good next year and the year beyond that |
| We drive really good process in doing it |
| And all of those things, if you look at even other joint procedures or even manual shoulder procedures, those contribute to a better experience for the patient and a better outcome for the patient |
| and outside of the U.S., installs were quite good in the third quarter |
| and we're very excited about it |
| So overall, we feel really good heading into next year |
| For that type of capital, it's still a very robust order environment |
| And then you combine that with the new releases that we've had of those products and I think we're in a good position to certainly capture market share and drive really good growth |
| But what I would say, to my previous comments, is we have really good momentum on price |
| And so we're very bullish on what we're going to be able to do with Pangea |
| There's a lot of smaller products that we'll launch that I know individually aren't as exciting, but there are products that will have fast growth and accretive growth |
| I would also say that for Stryker, we're also feeling the uplift that we're getting, say, from just our Mako footprint now that's out of the market, as well as our new hip stem |
| So super excited about that in the Trauma division, which we'll launch early next year |
| We have a good backlog there |
| The numbers for System 9 look really good so far |
| The other thing, frankly, as long as we can keep growing at high single digits or even low double digits, there's the opportunity to really drive leverage over fixed costs, and that just naturally comes |
| And so on the MedSurg side, we are still fairly bullish about what we can gain in price for next year |
| So all of that sort of information and process has really led us to be a lot more confident about how we're managing that process |
| So there is a lot of anticipation for LIFEPAK and I think, again, there, it will give a lot of momentum to our medical and emergency care businesses |
| I would tell you that the timelines are more elongated there maybe than they usually have been, but we still have a very healthy backlog |
| And we think that's a really good indicator of kind of Mako momentum |
| Question-and-Answer Session Q - Vijay Kumar So you guys had a pretty bullish Analyst Day, year-to-date trends have been really strong |
| And if you look at the complement with our new Insignia Hip and sort of the software that we have on Mako, it works really well |
| Statement |
|---|
| And it's been a little confusing because some of your peers have cited challenges by customers, signing great environment |
| So if it is new facilities, there still is sort of supply disruptions in the construction industry |
| Glenn Boehnlein Is this being recorded? Vijay Kumar Gross margins are still 200 basis points below pre-pandemic level |
| Vijay Kumar But the value proposition here is -- it's pretty clear, right? In a navigation, I think in Spine tends to be challenging |
| So I do think that pricing won't be as negative as it's been in the past is what I would say |
| We're seeing valuations come down |
| I think on the Orthopedics side, it's just less negative |
| There continues to be Neurovascular VBP, tender issues that are coming up |
| It's not that it's not competitive, and it's not that our customers aren't being mindful about how they spend their capital and these capital analysis committees and things like that still all exist |
| I mean, first of all, don't let me give you the wrong impression |
| So that hasn't really impacted them |
| And there's not a lot of pushback |
| There are a lot of patients that are not qualified for hip or knee procedures because of weight issues |
| We don't anticipate that slowing down |
| That's a question we've decidedly are not going to guide to |
| And so if the deal can't meet those hurdles, then we're essentially not going to do it |
Please consider a small donation if you think this website provides you with relevant information